Is there a potential of Circulating miRNAs as biomarkers in rheumatic diseases
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023728%3A_____%2F23%3AN0000041" target="_blank" >RIV/00023728:_____/23:N0000041 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/23:10466101
Result on the web
<a href="https://doi.org/10.1016/j.gendis.2022.08.011" target="_blank" >https://doi.org/10.1016/j.gendis.2022.08.011</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.gendis.2022.08.011" target="_blank" >10.1016/j.gendis.2022.08.011</a>
Alternative languages
Result language
angličtina
Original language name
Is there a potential of Circulating miRNAs as biomarkers in rheumatic diseases
Original language description
MicroRNAs (miRNAs) are small non-coding single-stranded RNAs of about 22 nucle-otides in length that act as post-transcriptional regulators of gene expression. Depending on the complementarity between miRNA and target mRNA, cleavage, destabilization, or transla-tional suppression of mRNA occurs within the RISC (RNA-induced silencing complex). As gene expression regulators, miRNAs are involved in a variety of biological functions. Dysregulation of miRNAs and their target genes contribute to the pathophysiology of many diseases, including autoimmune and inflammatory disorders. MiRNAs are also present extracellularly in their sta-ble form in body fluids. Their incorporation into membrane vesicles or protein complexes with Ago2, HDL, or nucleophosmin 1 protects them against RNases. Cell-free miRNAs can be deliv-ered to another cell in vitro and maintain their functional potential. Therefore, miRNAs can be considered mediators of intercellular communication. The remarkable stability of cell-free miRNAs and their accessibility in body fluid makes them potential diagnostic or prognostic bio-markers and potential therapeutic targets. Here we provide an overview of the potential role of circulating miRNAs as biomarkers of disease activity, therapeutic response, or diagnosis in rheumatic diseases. Many circulating miRNAs reflect their involvement in the pathogenesis, while for plenty, their pathogenetic mechanisms remain to be explored. Several miRNAs described as biomarkers were also shown to be of therapeutic potential, and some miRNAs are already tested in clinical trials. & COPY; 2022 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co., Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons. org/licenses/by-nc-nd/4.0/).
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30226 - Rheumatology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Genes and Diseases
ISSN
2352-4820
e-ISSN
2352-3042
Volume of the periodical
10
Issue of the periodical within the volume
4
Country of publishing house
NL - THE KINGDOM OF THE NETHERLANDS
Number of pages
16
Pages from-to
1263-1278
UT code for WoS article
001017364300001
EID of the result in the Scopus database
2-s2.0-85138804878